FDA Approves Nexavar For Patients With Inoperable Liver Cancer
Nov 20th 2007Drug InformationCancer
The U.S. Food and Drug Administration announced that it has approved Nexavar (sorafenib) for use in patients with a form of liver cancer known as hepatocellular carcinoma, when the cancer is inoperable. Nexavar was originally approved in 2005 for the treatment of patients with advanced renal cell carcinoma, a form of kidney cancer.”In a randomized clinical trial, the group of patients with inoperable hepatocellular carcinoma who received Nexavar survived 2. [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
